139 related articles for article (PubMed ID: 26293576)
1. CD146 as an adverse prognostic factor in uterine sarcoma.
Zhou Y; Huang H; Yuan LJ; Xiong Y; Huang X; Lin JX; Zheng M
Eur J Med Res; 2015 Aug; 20(1):67. PubMed ID: 26293576
[TBL] [Abstract][Full Text] [Related]
2. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma.
Pautier P; Genestie C; Rey A; Morice P; Roche B; Lhommé C; Haie-Meder C; Duvillard P
Cancer; 2000 Mar; 88(6):1425-31. PubMed ID: 10717626
[TBL] [Abstract][Full Text] [Related]
3. The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study.
Akhan SE; Yavuz E; Tecer A; Iyibozkurt CA; Topuz S; Tuzlali S; Bengisu E; Berkman S
Gynecol Oncol; 2005 Oct; 99(1):36-42. PubMed ID: 15992918
[TBL] [Abstract][Full Text] [Related]
4. Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence.
Goff BA; Rice LW; Fleischhacker D; Muntz HG; Falkenberry SS; Nikrui N; Fuller AF
Gynecol Oncol; 1993 Jul; 50(1):105-9. PubMed ID: 8349151
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers.
Koivisto-Korander R; Butzow R; Koivisto AM; Leminen A
Tumour Biol; 2011 Jun; 32(3):451-9. PubMed ID: 21161468
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors and survival of patients with uterine sarcoma: a German unicenter analysis.
Huss A; Klar M; Hasanov MF; Juhasz-Böss I; Bossart M
Arch Gynecol Obstet; 2023 Mar; 307(3):927-935. PubMed ID: 35780401
[TBL] [Abstract][Full Text] [Related]
7. Uterine sarcoma: the Hacettepe hospital experience of 88 consecutive patients.
Ayhan A; Tuncer ZS; Tanir M; Yüce K; Ayhan A
Eur J Gynaecol Oncol; 1997; 18(2):146-8. PubMed ID: 9105869
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis of p53 protein in uterine sarcomas.
Nordal RR; Kristensen GB; Stenwig AE; Tropé CG; Nesland JM
Gynecol Oncol; 1998 Jul; 70(1):45-8. PubMed ID: 9698472
[TBL] [Abstract][Full Text] [Related]
9. Expression of Ki-67, P53 and progesterone receptors in uterine smooth muscle tumors. Diagnostic value.
Petrović D; Babić D; Forko JI; Martinac I
Coll Antropol; 2010 Mar; 34(1):93-7. PubMed ID: 20437637
[TBL] [Abstract][Full Text] [Related]
10. Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan.
Sagae S; Yamashita K; Ishioka S; Nishioka Y; Terasawa K; Mori M; Yamashiro K; Kanemoto T; Kudo R
Oncology; 2004; 67(1):33-9. PubMed ID: 15459493
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors and expression of p53 and mdm-2 in uterine sarcomas.
Kim SH; Kim JW; Kim YT; Kim JH; Yoon BS; Ryu HS
Int J Gynaecol Obstet; 2006 Dec; 95(3):272-7. PubMed ID: 16930603
[TBL] [Abstract][Full Text] [Related]
12. Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system.
D'Angelo E; Spagnoli LG; Prat J
Hum Pathol; 2009 Nov; 40(11):1571-85. PubMed ID: 19540555
[TBL] [Abstract][Full Text] [Related]
13. Uterine leiomyosarcoma and endometrial stromal sarcoma have unique miRNA signatures.
Ravid Y; Formanski M; Smith Y; Reich R; Davidson B
Gynecol Oncol; 2016 Mar; 140(3):512-7. PubMed ID: 26768834
[TBL] [Abstract][Full Text] [Related]
14. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
15. Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma.
Davidson B; Hellesylt E; Holth A; Danielsen HE; Skeie-Jensen T; Katz B
Virchows Arch; 2017 Sep; 471(3):355-362. PubMed ID: 28643014
[TBL] [Abstract][Full Text] [Related]
16. Significance of lymph node metastasis on survival of women with uterine adenosarcoma.
Machida H; Nathenson MJ; Takiuchi T; Adams CL; Garcia-Sayre J; Matsuo K
Gynecol Oncol; 2017 Mar; 144(3):524-530. PubMed ID: 28109626
[TBL] [Abstract][Full Text] [Related]
17. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
[TBL] [Abstract][Full Text] [Related]
18. Ki-67 and vascular endothelial growth factor expression in uterine leiomyosarcoma.
Mayerhofer K; Lozanov P; Bodner K; Bodner-Adler B; Obermair A; Kimberger O; Czerwenka K
Gynecol Oncol; 2004 Jan; 92(1):175-9. PubMed ID: 14751154
[TBL] [Abstract][Full Text] [Related]
19. Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins.
Amada S; Nakano H; Tsuneyoshi M
Int J Gynecol Pathol; 1995 Apr; 14(2):134-42. PubMed ID: 8601525
[TBL] [Abstract][Full Text] [Related]
20. Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma.
Tsuyoshi H; Yoshida Y
Cancer Sci; 2018 Jun; 109(6):1743-1752. PubMed ID: 29660202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
